Current Report Filing (8-k)
November 17 2021 - 06:02AM
Edgar (US Regulatory)
None. cydy false 0001175680 0001175680
2021-11-16 2021-11-16
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
Current Report
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act
Date of Report (Date of earliest event reported): November 16,
2021
CytoDyn Inc.
(Exact name of registrant as specified in its charter)
|
|
|
|
|
Delaware |
|
000-49908 |
|
83-1887078 |
(State or other jurisdiction of
incorporation or organization)
|
|
(Commission
File Number)
|
|
(I.R.S. Employer
Identification No.)
|
1111 Main Street, Suite 660
Vancouver, Washington 98660
(Address of principal executive offices, including zip code)
(360) 980-8524
(Registrant’s telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
|
☐ |
Written communications pursuant to Rule 425 under the Securities
Act (17 CFR 230.425)
|
|
☐ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
|
|
☐ |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
|
|
☐ |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of the
Act:
|
|
|
|
|
Title of each class
|
|
Trading
Symbol(s)
|
|
Name of each exchange
on which registered
|
None |
|
None |
|
None |
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933
(§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange
Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period
for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act.
☐
Item 8.01. Other Events.
On November 16, 2021, CytoDyn Inc. issued a press release
reminding shareholders to register for the 2021 Annual Meeting of
Stockholders, which will be held on November 24, 2021. A copy
of the press release is attached hereto as Exhibit 99.1 and is
incorporated herein by reference.
Item 9.01 Financial Statements and Exhibits
(d) Exhibits
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of
1934, the registrant has duly caused this report to be signed on
its behalf by the undersigned hereunto duly authorized.
|
|
|
|
|
|
|
Date: November 16, 2021 |
|
|
|
|
|
CYTODYN
INC. |
|
|
|
|
|
|
|
|
By: |
|
/s/ Antonio Migliarese
|
|
|
|
|
|
|
Antonio
Migliarese |
|
|
|
|
|
|
Chief
Financial Officer |
CytoDyn (QB) (USOTC:CYDY)
Historical Stock Chart
From Aug 2023 to Sep 2023
CytoDyn (QB) (USOTC:CYDY)
Historical Stock Chart
From Sep 2022 to Sep 2023